 Allena Pharmaceuticals, Inc. ALNA, a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the third quarter ended September 30, 2019 and also provided a business update. We are excited about the presentation of positive topline results from URIROX-1 and Study 206 in EH patients that we presented at the American Society of Nephrology ASN Annual Meeting, said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. 